Imaging of opioid receptors in the central nervous system

Brain

Volumn 131, Issue 5, 2008, Pages 1171-1196

  Henriksen, Gjermund ^a,b   Willoch, Frode ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OSLO   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Addiction; Epilepsy; Opioid receptors; Pain; PET

Indexed keywords

4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; 4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER C 11; 6 O FLUOROETHYL 6 O NORDIPRENORPHINE F 18; BUPRENORPHINE; CARFENTANIL; CARFENTANIL C 11; CYCLOFOXY; DELTA OPIATE RECEPTOR; DIPRENORPHINE; DIPRENORPHINE C 11; DOPAMINE; FLUOROCYCLOFOXY F 18; FLUORODEOXYGLUCOSE F 18; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; METHADONE; METHYL NALTRINDOLE C 11; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALMEFENE; NALOXONE; NALTRINDOLE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; RACLOPRIDE C 11; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; LIGAND; OPIATE RECEPTOR;

ALCOHOLISM; ALZHEIMER DISEASE; AUTORADIOGRAPHY; BINDING AFFINITY; BULIMIA; CANCER PAIN; CHRONIC PAIN; DEMENTIA; DESENSITIZATION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG TOLERANCE; EATING DISORDER; HUMAN; HUNTINGTON CHOREA; LIGAND BINDING; MOTOR DYSFUNCTION; NEUROCHEMISTRY; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPIATE ADDICTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RESTLESS LEGS SYNDROME; REVIEW; TEMPORAL LOBE EPILEPSY; WITHDRAWAL SYNDROME; ADDICTION; BRAIN; BRAIN MAPPING; EPILEPSY; METABOLISM; METHODOLOGY; PAIN; PHYSIOLOGY; SCINTISCANNING;

BRAIN; BRAIN MAPPING; EPILEPSY; HUMANS; LIGANDS; MOVEMENT DISORDERS; PAIN; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, OPIOID; SUBSTANCE-RELATED DISORDERS;

EID: 44949187620     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm255     Document Type: Review

References (152)

1. Abbadie C, Pan YX, Pasternak GW. Immunohistochemical study of the expression of exon11-containing mu opioid receptor variants in mouse brain. Neuroscience 2004; 127: 419-30.
2. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 2003; 100: 1740-4.
3. Austin MC, Kalivas PW. Enkephalinergic and GABAergic modulation of motor activity in the ventral pallidum. J Pharmacol Exp Ther 1990; 252: 1370-7.
4. Bajorek JG, Lee RJ, Lomax P. Neuropeptides: anticonvulsant and convulsant mechanisms in epileptic model systems and in humans. Adv Neurol 1986; 44: 489-500.
5. Barinaga M. Neuroimaging. Still debated, brain image archives are catching on. Science 2003; 300: 43-5.
6. Bartenstein PA, Duncan JS, Prevett MC, Cunningham VJ, Fish DR, Jones AK, et al. Investigation of the opioid system in absence seizures with positron emission tomography. J Neurol Neurosurg Psychiatry 1993; 56: 1295-302.
7. Bartenstein PA, Prevett MC, Duncan JS, Hajek M, Wieser HG. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. Epilepsy Res 1994; 18: 119-25.
8. Baumgartner U, Buchholz HG, Bellosevich A, Magerl W, Siessmeier T, Rolke R, et al. High opiate receptor binding potential in the human lateral pain system. Neuroimage 2006; 30: 692-9.
9. Beckett AH, Casy AF. Synthetic analgesics: stereochemical considerations. J Pharm Pharmacol 1954; 6: 986-1001.
10. 11C]carfentanil and positron emission tomography (PET). Pain 2002; 99: 589-98.
11. Bencherif B, Guarda AS, Colantuoni C, Ravert HT, Dannals RF, Frost JJ. Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J Nucl Med 2005; 46: 1349-51.
12. 11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 2004; 55: 255-62.
13. Brooks DJ, Piccini P, Turjanski N, Samuel M. Neuroimaging of dyskinesia. Ann Neurol 2000; 47: S154-8.
14. 11C]diprenorphine PET study. Brain 1995; 118: 951-8.
15. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JP, Lau J. Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 23-31.
16. Casey KL. Central pain: distributed effects of focal lesions. Pain 2004; 108: 205-6.
17. Celerier E, Laulin JP, Corcuff JB, Le MM, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001; 21: 4074-80.
18. Chung SK, Cohen RS, Pfaff DW. Transneuronal degeneration in the midbrain central gray following chemical lesions in the ventromedial nucleus: a qualitative and quantitative analysis. Neuroscience 1990; 38: 409-26.
19. Clapham DE, Neer EJ. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 1997; 37: 167-203.
20. Cohen RM, Andreason PJ, Doudet DJ, Carson RE, Sunderland T. Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. J Neurol Sci 1997; 148: 171-80.
21. Cohen RM, Carson RE, Aigner TG, Doudet DJ. Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Res 1998; 806: 292-6.
22. Cohen RM, Carson RE, Saunders RC, Doudet DJ. Opiate receptor avidity is increased in rhesus monkeys following unilateral optic tract lesion combined with transections of corpus callosum and hippocampal and anterior commissures. Brain Res 2000b; 879: 1-6.
23. Cohen RM, Carson RE, Sunderland T. Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. Synapse 2000a; 38: 226-9.
24. Cohen RM, Carson RE, Wyatt RJ, Doudet DJ. Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP. Synapse 1999; 33: 282-8.
25. Connor M, Christie MDJ. Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 1999; 26: 493-9.
26. 3H]naltrindole: a potent and selective ligand for labeling delta-opioid receptors. Brain Res 1993; 604: 160-4.
27. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993; 13: 15-23.
28. DeHaven-Hudkins DL, Brostrom PA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV, et al. Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 1990; 37: 497-504.
29. Devi LA. Heterodimerization of G protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001; 22: 532-7.
30. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48: 567-92.
31. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987; 27: 233-9.
32. Eriksen J, Jensen MK, Sjogren P, Ekholm O, Rasmussen NK. Epidemiology of chronic non-malignant pain in Denmark. Pain 2003; 106: 221-8.
33. Fan LW, Tien LT, Tanaka S, Ma T, Chudapongse N, Sinchaisuk S, et al. Changes in the brain kappa-opioid receptor levels of rats in withdrawal from physical dependence upon butorphanol. Neuroscience 2003; 121: 1063-74.
34. Fichna J, Janecka A, Costentin J, Do Rego JC. The endomorphin system and its evolving neurophysiological role. Pharmacol Rev 2007; 59: 88-123.
35. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000; 25: 195-200.
36. Frey S, Petrides M. Re-examination of the human taste region: a positron emission tomography study. Eur J Neurosci 1999; 11: 2985-8.
37. Frost JJ. Receptor localization and quantification with PET. Radiology 1988; 169: 273-4.
38. 11C]carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab 1989; 9: 398-409.
39. Frost JJ, Mayberg HS, Fisher RS, Douglass KH, Dannals RF, Links JM, et al. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 1988; 23: 231-7.
40. Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr 1985; 9: 231-6.
41. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004; 27: 107-44.
42. Gjedde A. Calculation of cerebral glucose phosphorylation from brai uptake of glucose analogs in vivo: a re-examination. Brain Res Rev 1982; 4: 237-74.
43. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M, et al. maging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 2005; 57: 1573-82.
44. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 2007; 61: 101-10.
45. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003; 28: 2000-9.
46. Guderman T, Kalkbrenner F, Schultz G. Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 1996; 36: 429-59.
47. Gulya K. The opioid system in neurologic and psychiatric disorders and in their experimental models. Pharmacol Ther 1990; 46: 395-428.
48. Gunn RN, Gunn SR, Turkheimer FE, Aston JA, Cunningham VJ. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 2002; 22: 1425-39.
49. Haber SN, Watson SJ. The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal forebrain. Neuroscience 1985; 14: 1011-24.
50. Hackler L, Zadina JE, Ge L-J, Kastin AJ. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997; 18: 1635-9.
51. Hammers A, Asselin MC, Hinz R, Kitchen I, Brooks DJ, Duncan JS, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 2007; 30: 1009-16.
52. Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psych 2005; 62: 57-64.
53. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999; 22: 970-99.
54. Henriksen G, Willoch F, Talbot PS, Wester HJ. Recent development and potential use of μ- and κ-opioid receptor ligands in positron emission tomography. Drug Dev Rev 2006; 67: 890-904.
55. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacol (Berl) 1997; 129: 99-111.
56. Hiller JM, Fan LQ. Laminar distribution of the multiple opioid receptors in the human cerebral cortex. Neurochemical Research 1996; 21: 1333-45.
57. 11C]diprenorphine to agonist opiates. J Pharmacol Exp Ther 2007; 322: 661-67.
58. Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001; 42: 755-63.
59. Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, et al. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005; 30: 2245-53.
60. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
61. Jones AK, Cunningham VJ, Ha-Kawa S, Fujiwara T, Luthra SK, Silva S, et al. Changes in central opioid receptor binding in relation to inflammation and pain in patients with rheumatoid arthritis. Br J Rheumatol 1994; 33: 909-16.
62. 11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 1999; 19: 803-8.
63. Jones AK, Qi LY, Fujirawa T, Luthra SK, Ashburner J, Bloomfield P, et al. In vivo distribution of opioid receptors in man in relation to the cortical projections of the medial and lateral pain systems measured with positron emission tomography. Neurosci Lett 1991; 126: 25-8.
64. 11C]diprenorphine binding and PET. Eur J Pain 2004; 8: 479-85.
65. Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complexes. Neuropsychopharmacology 2000; 23: S5-18.
66. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63: 1199-208.
67. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. Clin Invest 1948; 27: 476-83.
68. Kim S, Wagner HN Jr, Villemagne VL, Kao PF, Dannals RF, Ravert HT, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med 1997; 38: 1726-31.
69. 18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000; 295: 1070-6.
70. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, et al. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995; 9: 516-25.
71. Koepp MJ, Richardson MP, Brooks DJ, Duncan JS. Focal cortical release of endogenous opioids during reading-induced seizures. Lancet 1998; 352: 952-5.
72. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710-26.
73. Laruelle M, Slifstein M, Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 2002; 27: 287-99.
74. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40: 389-430.
75. Lesscher HMB, Bailey A, Burbach JPH, van Ree JM, Kitchen I, Gerrits MAFM. Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci 2003; 17: 1006-12.
76. Lever JR, Dannals RF, Wilson AA, Ravert HT, Frost JJ, Wagner HN Jr. Synthesis of carbon-11 labeled diprenorphine: a radioligand for positron emission tomography studies of opiate receptors. Tetrahedon Lett 1987; 28: 4015-8.
77. Liberzon I, Taylor SF, Phan KL, Britton JC, Fig LM, Bueller JA, et al. Altered central mu-opioid receptor binding after psychological trauma. Biol Psychiatry 2007; 6: 1030-8.
78. 11C-methyl]cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-7.
79. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-40.
80. Maarrawi J, Peyron R, Mertens P, Costes N, Magnin M, Sindou M, et al. Differential brain opioid receptor availability in central and peripheral neuropathic pain. Pain 2007; 127: 183-9.
81. Madar I, Lesser RP, Krauss G, Zubieta JK, Lever JR, Kinter CM, et al. Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography. Ann Neurol 1997; 41: 358-67.
82. 11C]methyl)naltrindole and PET. Synapse 1996; 24: 19-28.
83. Malizia AL. What do brain imaging studies tell us about anxiety disorders? J Psychopharmacol 1999; 13: 372-8.
84. Mansour A, Watson SJ, Akil H. Opioid receptors: past, present and future. Trends Neurosci 1995; 18: 69-70.
85. Maurer R, Cortes R, Probst A, Palacios JM. Multiple opiate receptor in human brain: an autoradiographic investigation. Life Sci 1983; 33 (Suppl 1): 231-4.
86. Mayberg HS, Sadzot B, Meltzer CC, Fisher RS, Lesser RP, Dannals RF, et al. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol 1991; 30: 3-11.
87. 11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharm Exp Ther 2005; 312: 309-15.
88. Meltzer CC, Zubieta JK, Links JM, Brakeman P, Stumpf MJ, Frost JJ. MR-based correction of brain PET measurements for heterogeneous gray matter radioactivity distribution. J Cereb Blood Flow Metab 1996; 16: 650-8.
89. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377: 532-5.
90. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-27.
91. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341: 33-8.
92. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296: 1636-9.
93. Noble EP. Alcoholism and the dopaminergic system: a review. Addict Biol 1996; 1: 333-48.
94. 11C]methyl-Ro 64-6198 as an ORL1 receptor imaging agent. Nucl Med Biol 2001; 28: 941-7.
95. Pan YX, Xu J, Bolan E, Moskowitz HS, Xu M, Pasternak GW. Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol 2005; 68: 866-75.
96. Pasternak DA, Pan L, Xu J, et al. Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy. J Neurochem 2004; 91: 881-90.
97. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-90.
98. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
99. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973; 179: 1011-4.
100. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with 2-[F-18]fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-88.
101. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42: 720-6.
102. Portoghese PS. A new concept on the mode of interaction of narcotic analgesics with receptors. J Med Chem 1965; 8: 609-16.
103. 11C] diprenorphine and positron emission tomography. Epilepsy Res 1994; 19: 71-7.
104. Quock RM, Burkey TH, Varga E, et al. The d-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev 1999; 51: 503-32.
105. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 1994; 45: 330-4.
106. Reimold M, Slifstein M, Heinz A, Mueller-Schauenburg W, Bares R. Effect of spatial smoothing on t-maps: arguments for going back from t-maps to masked contrast images. J Cereb Blood Flow Metab 2006; 26: 751-9.
107. Rios CD, Jordan BA, Gomes I, Devi LA. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 2001; 92: 71-87.
108. 11C]diprenorphine PET, mRNA expression and autoradiography. Neuroreport 1999; 10: 619-24.
109. Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, et al. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 2007b; 32: 450-7.
110. 11C]raclopride binding potential after a non-pharmacological challenge. Synapse 2007a; 61: 707-14.
111. Seizinger BR, Liebisch DC, Kish SJ, Arendt RM, Hornykiewicz O, Herz A. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system. Brain Res 1986; 378: 405-8.
112. Self DW, Stein L. Receptor subtypes in opioid and stimulant reward. Pharmacol Toxicol 1992; 70: 87-94.
113. Shuster SJ, Riedl M, Li X, Vulchanova L, Elde R. Stimulus-dependent translocation of kappa opioid receptors to the plasma membrane. J Neurosci 1999; 19: 2658-64.
114. Siggins GR, Henriksen SJ, Chavkin C, Gruol D. Opioid peptides and epileptogenesis in the limbic system: cellular mechanisms. Adv Neurol 1986; 44: 501-12.
115. Simmons ML, Chavkin C. Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol 1996; 39: 145-96.
116. 3H]Etorphine to rat-brain homogenate. Proc Natl Acad Sci USA 1973; 70: 1947-9.
117. Simon MI, Strathmann MP, Gautam N. Diversity of G proteins in signal transduction. Science 1991; 252: 802-8.
118. 11C]methyl) naltrindole and positron emission tomography. J Cereb Blood Flow Metab 1999; 19: 956-66.
119. Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 2006; 26: 5777-85.
120. Smith YR, Zubieta JK, del Carmen MG, Dannals RF, Ravert HT, Zacur HA, et al. Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones. J Clin Endocrinol Metabol 1998; 83: 4498-505.
121. Soderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000; 113: 85-96.
122. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
123. Sprenger T, Valet M, Boecker H, Henriksen G, Spilker ME, Willoch F, et al. Opioidergic activation in the medial pain system after heat pain. Pain 2006a; 122: 63-7.
124. Sprenger T, Willoch F, Miederer M, Schindler F, Valet M, Berthele A, et al. Opioidergic changes in the pineal gland and hypothalamus in cluster headache: a ligand PET study. Neurology 2006b; 66: 1108-10.
125. Strader CD, Fong TM, Tota MR, Underwood D, Dixon RAF. Structure and function of G protein-coupled receptors. Annu Rev Biochem 1994; 63: 101-32.
126. 11C]GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. J Nucl Med 2005; 46: 484-94.
127. 18F]cyclofoxy. Epilepsy Res 1992; 13: 129-39.
128. Tortella FC. Endogenous opioid peptides and epilepsy: quieting the seizing brain? Trends Pharmacol Sci 1988; 9: 366-72.
129. Tsao P, Cao T, von ZM. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 2001; 22: 91-6.
130. Tsao PI, von Zastrow M. Diversity and specificity in the regulated endocytic membrane trafficking of G-protein-coupled receptors. Pharmacol Ther 2001; 89: 139-47.
131. Varga EV, Yamamura HI, Rubenzik MK, Stropova D, Navratilova E, Roeske WR. Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. Life Sci 2003; 74: 299-311.
132. van Ree JM, Gerrits MA, Vanderschuren LJ. Opioids, reward and addiction: An encounter of biology, psychology, and medicine. Pharmacol Rev 1999; 51: 341-96.
133. Vogt BA, Watanabe H, Gootoonk S, Jones AKP. Topography of diprenorphine binding in human cingulate gyrus and adjacent cortex derived from coregistered PET and MR images. Human Brain Mapp 1995; 3: 1-12.
134. 11C] diprenorphine PET study. Brain 2005; 128: 906-17.
135. Wagner JJ, Terman GW, Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 1993; 363: 451-4.
136. 11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 2000; 41: 522-30.
137. 11C]Diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab 1997; 17: 943-9.
138. 11C] diprenorphine PET study. Mov Disord 2004; 19: 1498-503.
139. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001; 81: 299-343.
140. Willoch F, Tölle TR, Wester HJ, Munz F, Petzold A, Schwaiger M, et al. Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. AJNR Am J Neuroradiol 1999; 20: 686-90.
141. Willoch F, Gamringer U, Medele R, Steude U, Tolle TR. Analgesia by electrostimulation of the trigeminal ganglion in patients with trigeminopathic pain: a PET activation study. Pain 2003; 103: 119-30.
142. 11C]diprenorphine PET study. Pain 2004; 108: 213-20.
143. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-502.
144. Zagon IS, Gibo DM, McLaughlin PJ. Adult and developing human cerebella exhibit different profiles of opioid binding sites. Brain Res 1990; 523: 62-8.
145. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000; 23: 326-34.
146. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005; 25: 7754-62.
147. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psyschiatry 1999; 156: 842-8.
148. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 1996; 2: 1225-9.
149. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003a; 299: 1240-3.
150. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 2003b; 60: 1145-53.
151. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci 2002; 22: 5100-7.
152. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 311-5.